SCHEMBL20102448

SCHEMBL20102448

CCCCCc1ccc2cc(-c3cc4c(c(F)c3F)-c3c-4ccc(OCC)c3F)ccc2c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 2/20 0.38
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
FGFR1 P11362 1/20 0.35
RARB P10826 3/20 0.35
CALM1 P0DP23 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
MPL P40238 2/20 0.32
FFAR4 Q5NUL3 1/20 0.32
RARA P10276 1/20 0.32
RARG P13631 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20102437 0.90 RARB (0.43) FGFR2MAPTRAB9AL3MBTL1RARB
SCHEMBL20102438 0.84 RARB (0.37) MAPTRAB9AL3MBTL1RARB
SCHEMBL20111597 0.83 S1PR1 (0.44) FGFR2RAB9AL3MBTL1FGFR1
SCHEMBL20102550 0.79 RARB (0.38) FGFR2MAPTRAB9AL3MBTL1FGFR1
SCHEMBL20102464 0.79 SMPD1 (0.41) MAPTRAB9AL3MBTL1RARB
SCHEMBL8942430 0.79 CNR2 (0.39) MAPTRAB9AL3MBTL1RARBGABRA1
SCHEMBL20102562 0.78 HTT (0.39) MAPTL3MBTL1RARB
SCHEMBL8615249 0.78 RARB (0.47) MAPTRAB9AL3MBTL1RARBMPL
SCHEMBL20102405 0.77 FGFR2 (0.34) FGFR2MAPTL3MBTL1
SCHEMBL8972213 0.76 RARB (0.46) MAPTRAB9AL3MBTL1RARBMPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE YBX1, PIEZO1, C1S FGFR2 168/4885MAPT 952/4885RAB9A 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.